AQXP vs. ZNTL, LBPH, ARQT, ETNB, ELVN, PRTC, TNGX, AUPH, SAGE, and OCUL
Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Longboard Pharmaceuticals (LBPH), Arcutis Biotherapeutics (ARQT), 89bio (ETNB), Enliven Therapeutics (ELVN), PureTech Health (PRTC), Tango Therapeutics (TNGX), Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), and Ocular Therapeutix (OCUL). These companies are all part of the "medical" sector.
Aquinox Pharmaceuticals (NASDAQ:AQXP) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Aquinox Pharmaceuticals has a beta of -7.37, indicating that its share price is 837% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by insiders. Comparatively, 6.1% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aquinox Pharmaceuticals' return on equity of -30.13% beat Zentalis Pharmaceuticals' return on equity.
Aquinox Pharmaceuticals received 249 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 64.10% of users gave Zentalis Pharmaceuticals an outperform vote.
Aquinox Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals.
In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. Aquinox Pharmaceuticals' average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score.
Zentalis Pharmaceuticals has a consensus target price of $38.57, indicating a potential upside of 247.18%. Given Zentalis Pharmaceuticals' higher probable upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.
Summary
Aquinox Pharmaceuticals beats Zentalis Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Get Aquinox Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquinox Pharmaceuticals Competitors List
Related Companies and Tools
